GlassScriptPhysician profile
Jason S Starr
NPI 1205090107
$30,235.87
in general payments reported to CMS, 2019-2025
28 companies · $7,729 in 2025
The $7,729 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $5,354 · 2021: $14K · 2022: $641 · 2023: $217 · 2024: $2,290 · 2025: $7,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,680 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,296 · Honoraria: $1,575 · Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,680.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,296.00 |
| Honoraria | $1,575.00 |
| Food and Beverage | $685.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $4,924.75 | 2019-2025 | Somatuline Depot, Onivyde |
| Taiho Oncology, INC. | $4,337.50 | 2020-2021 | |
| Exelixis INC. | $4,003.55 | 2024-2025 | Cabometyx |
| Tersera Therapeutics LLC | $3,974.22 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $3,296.00 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $2,655.00 | 2021 | |
| Array Biopharma INC | $2,520.00 | 2020 | |
| Advanced Accelerator Applications | $1,485.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,480.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,155.80 | 2022-2025 | |
| Genentech USA, INC. | $125.45 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $106.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.64 | 2023-2024 | |
| Foundation Medicine, INC. | $28.15 | 2022 | |
| Tempus Ai, INC | $27.74 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $24.63 | 2023 | Qinlock |
| Gilead Sciences, INC. | $11.92 | 2021 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.